You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Administrative Supplement to restore fee funds
SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. Topic: NINDSProject Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Protein ProFiler Microfluidic Electrophoresis System for Proteomics
SBC: INNOVAREGI LLC Topic: 400AbstractThe current estimate of the number of human genes is aboutin contrast to the number of presumed proteinswhich likely exceeds one millionThis increased complexity is the result of post transcriptional and post translational modificationsPTMsoccurring at multiple sites and in a quantitative variable mannerThe overwhelming result is a combinatorially expanding complexity of proteoforms that i ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Direct Delivery of Nucleic Acid Therapeutics
SBC: FHC, INC. Topic: NIMHProject Summary While nucleic acid therapeutics have shown promise in rodent and nonhuman primate models of CNS diseasesall double blind clinical trials to date have failedOne likely explanation for this failure is poor therapeutic distribution in targeted brain regionsFor examplepost mortem studies of patients with Parkinsonandapos s Disease receiving intraparenchymal injections of AAV NTN demons ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke
SBC: BioTime, Inc. Topic: 100ABSTRACT Stroke is a leading cause of disability worldwideGloballythere aremillion stroke survivors each year who have significant neurological deficits including sensory and motor disabilityleading to excessive socioeconomic burdenCell therapy using primary MSCs has been actively explored by us and others as a therapeutic solution to this unmet medical needHoweversince the therapeutic efficacy of ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100
SBC: NEONC TECHNOLOGIES INC Topic: 102Project Summary Abstract Many pharmaceutical agents are highly potentbut are unable to exert substantial therapeutic activity against disorders of the brainbecause the blood brain barrierBBBeffectively prevents their access to the site of intracerebral diseaseFor examplethe majority of glioblastoma patientsdespite the best efforts of current medical caredie within two years after diagnosisHencethe ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
O-Glycan-dependent Immunotherapy for Cancer
SBC: GLYTR THERAPEUTICS, INC. Topic: 102Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD
SBC: ONL Therapeutics, Inc. Topic: NEIPROJECT SUMMARYABSTRACT Age related macular degenerationAMDis the leadingand due to the aging baby boomersa growing cause of irreversible vision loss in the United Statesand is strongly associated with exposure to cigarette smokeCSand high fat dietsHFDWhile effective treatment is available for neovascular AMDthe AREDS II antioxidant vitamins are the only proven treatment for intermediate dry AMDUn ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Clinical Translation of a Caveolae Targeting Antibody for Enhancing Cancer Drug Delivery
SBC: Cavatar LLC Topic: NCIPROJECT SUMMARY This proposal aims to develop a novel caveolae targeting antibody for rapid clinical translationIts long term objective is to develop the caveolae pumping systeman active transendothelial transport pathwayto provide an effective solution to the delivery and toxicity problem of systemically administered chemotoxinsWork will be based on the current proprietary mouse monoclonal antibo ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
The Microscopic Imaging of Epigenetic Landscape- NeuroDevelopment (MIEL-ND) assay: a high throughput platform to screen compounds for neurodevelopmental effects
SBC: VALA SCIENCES, INC. Topic: 101Neurodevelopmental diseasesNDDsAutism Spectrum DisorderASDIntellectual DisabilitiesBipolar disordersand Schizophreniaetcare prevalent and due to errors in neurodifferentiation and neurocircuitryWhile NDDsin many casesare due to inherited mutationsevidence is mounting that prenatal exposure to environmental toxicants also cause NDDs via disruption of epigeneticse gmodifications of histoneshistone t ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity
SBC: SignalRx Pharmaceuticals Inc. Topic: 102Three CDKinhibitors were recently approved to treat breast cancerBrCAin combination regimentsDespite significant clinical activitytreatment of BrCA patients with these combinations does not result in a durable responseHencethere is an unmet medical need to develop targeted therapeutic agents which will augment the activity of CDKinhibitors in BrCA and other CDKcyclin D Myc dependent malignanciesA ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health